Vancouver, British Columbia – TheNewswire – June 11, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (“MindBio”), (the “Company”), a clinical-stage biopharma/biotechnology company dedicated to developing novel and effective mental health treatments, is pleased to...Read more
Treatment reversed tremors, ataxia, anxiety-like behavior, liver and kidney pathology damage, reduced copper accumulation, normalized ALT, AST, and bilirubin levels, and improved survival. Building on previous data in Werner syndrome, showing Telomir-1 reset the epigenetic clock,...Read more
Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events (“AEs”) as compared to injected liraglutide (Saxenda(R)) Lexaria has now demonstrated, in distinct human clinical studies, clear reductions in AEs utilizing its patented DehydraTECH technology...Read more
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway...Read more
Approval follows Priority Review and is supported by the robust TRUST clinical program, in which IBTROZI treatment demonstrated high, durable response rates and brain-penetrant efficacy across different lines of therapy The safety and tolerability of IBTROZI have been well established in the...Read more
MAVYRET® (glecaprevir/pibrentasvir) is the first and only oral eight-week pangenotypic treatment option approved for people with acute or chronic hepatitis C virus (HCV)* With this approval, providers can now treat HCV patients immediately at the time of diagnosis HCV is a curable condition,...Read more
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Regencell Bioscience | 39.05 6.35 | $653.73 |
| McKesson | 12.90 1.83 | $717.76 |
| Madrigal Pharmaceuticals | 12.02 4.26 | $294.34 |
| Insmed | 7.03 7.73 | $97.96 |
| UnitedHealth | 6.40 2.11 | $310.19 |
| Bolt Biotherapeutics | 5.97 1,068.16 | $6.53 |
| Tenet Healthcare | 4.85 3.10 | $161.41 |
| Veeva Systems | 4.42 1.56 | $288.55 |
| Kazia Therapeutics | 4.34 82.51 | $9.60 |
| Nutex Health | 3.60 3.07 | $120.77 |
| Insulet | 3.51 1.17 | $302.24 |
| Glaukos | 3.51 3.67 | $99.15 |
| Verona Pharma | 3.27 3.77 | $90.05 |
| Danaher | 2.10 1.04 | $204.72 |
| TransMedics | 2.02 1.43 | $142.88 |
| Ligand Pharmaceuticals | 1.97 1.74 | $115.39 |
| LENZ Therapeutics | 1.92 6.84 | $30.00 |
| GRAIL | 1.72 4.08 | $43.87 |
| Company | Volume | Last Trade |
|---|---|---|
| Healthcare Triangle | 972,791,621 | $0.009 |
| NuCana | 777,245,496 | $0.16 |
| Catheter Precision | 574,615,905 | $0.75 |
| Nuwellis | 433,039,177 | $0.36 |
| Electromedical Technologies | 149,184,671 | $0.00 |
| Helius Medical Technologies | 127,299,199 | $0.53 |
| NanoVibronix | 98,760,488 | $1.19 |
| Vaxart | 92,986,569 | $0.51 |
| Kazia Therapeutics | 49,328,547 | $9.60 |
| Pfizer | 37,335,365 | $24.48 |
| Carisma Therapeutics | 35,650,549 | $0.59 |
| Incannex Healthcare | 34,545,443 | $0.20 |
| Renovaro | 33,331,981 | $0.35 |
| Recursion | 32,657,374 | $5.40 |
| Nuvation Bio | 31,436,269 | $2.21 |
| AbCellera Biologics | 20,029,949 | $3.23 |
| Iovance Biotherapeutics | 17,126,264 | $2.24 |
| Onconetix | 16,151,182 | $0.07 |
| Tempus AI | 16,117,188 | $70.78 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
